Aligos Therapeutics(us:ALGS)

    39.84

    +3.89%

    Updated on 2024-12-22

    Open:36.78
    Close:39.84
    High:41.64
    Low:36.35
    Pre Close:38.35
    Volume:469153.00
    Amount:18.38M
    Turnover:13.08%
    Shares:3.59M
    MarketCap:142.94M
    DateTotalTotal SharesTotal RatioNewIncreasedDecreased
    2024-06-305618915982.37%81120
    2024-03-31514621390661.07%11138
    2023-12-31454535005960.39%9813
    2023-09-30432573420559.16%2317
    2023-06-30492628877160.43%3521
    2023-03-31482729041163.55%91314
    2022-12-31532650306161.75%11128
    2022-09-30652762492564.52%51230
    dateorgNametotalratiochangeShareschangeRatio
    2024-03-31Armistice Capital, Llc68934109.11%595350.87%
    2024-03-31Ecor1 Capital, Llc63894688.44%0
    2024-03-31Deep Track Capital, Lp61027708.07%0
    2024-03-31Vivo Capital, Llc35470304.69%0
    2024-03-31Altitude Crest Partners Inc.28446813.76%0
    2024-03-31Adage Capital Partners Gp, L.L.C.24645053.26%2464505
    2024-03-31Versant Venture Management, Llc23203813.07%0
    2024-03-31Baker Bros. Advisors Lp20764002.74%0
    2024-03-31Hhlr Advisors, Ltd.19061912.52%0
    2024-03-31Tang Capital Management Llc16500002.18%-539847-24.65%

    About

    Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.
    Address:1 Corporate Drive,2nd floor

    Market Movers